Last reviewed · How we verify
Ganovo+ritonavir+/-Interferon nebulization
This combination therapy uses Ganovo (an antiviral nucleoside analog) with ritonavir (a protease inhibitor booster) and optional interferon nebulization to inhibit viral replication and enhance immune response.
This combination therapy uses Ganovo (an antiviral nucleoside analog) with ritonavir (a protease inhibitor booster) and optional interferon nebulization to inhibit viral replication and enhance immune response. Used for COVID-19 (based on institutional use at Ninth Hospital of Nanchang), Severe respiratory viral infections.
At a glance
| Generic name | Ganovo+ritonavir+/-Interferon nebulization |
|---|---|
| Sponsor | The Ninth Hospital of Nanchang |
| Drug class | Antiviral combination therapy |
| Target | Viral RNA-dependent RNA polymerase; CYP3A4 (ritonavir); Interferon-alpha/beta receptors |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Ganovo acts as a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, while ritonavir enhances bioavailability by inhibiting cytochrome P450 metabolism. Interferon nebulization provides direct pulmonary immune stimulation and antiviral activity at the site of infection, particularly relevant for respiratory viral infections.
Approved indications
- COVID-19 (based on institutional use at Ninth Hospital of Nanchang)
- Severe respiratory viral infections
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea)
- Hepatotoxicity
- Interferon-related flu-like symptoms
- Hyperuricemia
Key clinical trials
- Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: